Chinook Therapeutics, Inc.
NASDAQ: KDNY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric L. Dobmeier
- Employees
- 214
- Headquarters
- Seattle, United States
- IPO year
- 2020
- Market cap
- $2.7B
- Website
- https://www.chinooktx.com
Loading KDNY…
Loading profile data…Frequently asked questions about KDNY
What does Chinook Therapeutics, Inc. (KDNY) do?
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinic...
Where does KDNY trade?
Chinook Therapeutics, Inc. (KDNY) trades on the NASDAQ Global Select.
What sector is KDNY in?
Chinook Therapeutics, Inc. (KDNY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chinook Therapeutics, Inc.?
Eric L. Dobmeier is the chief executive officer of Chinook Therapeutics, Inc. (KDNY).
Where is Chinook Therapeutics, Inc. headquartered?
Chinook Therapeutics, Inc. is headquartered in United States.
Does KDNY pay a dividend?
Chinook Therapeutics, Inc. (KDNY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KDNY go public?
Chinook Therapeutics, Inc. (KDNY) completed its initial public offering in 2020.